bpc 157 fda ind BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers BPC-157 Before the FDA: Briefing
Description
Behavioral and feeding therapies are essential components of intervention

Heavy metals (lead): under 0.5 ppm (spec 1 ppm or less)

Age and health status can change the dosage

Therefore, the patients stomach will not be able to absorb the B12 again, no matter how much time has passed since the surgery
